Literature DB >> 6509448

Progestin and estrogen receptors in human meningioma.

M A Blankenstein, G Blaauw, S W Lamberts.   

Abstract

Progestin receptors (PR) were detected with a dextran-coated charcoal assay and Scatchard plot analysis in 40 of 45 cytosols from human meningioma. The mean PR level in samples from female patients (297 +/- 104 fmol/mg protein; mean +/- SEM; n = 28) was not different from that in samples from male patients (190 +/- 76; n = 12). No differences were observed in the PR content of meningiomas resected from different locations. In the three cases studied, nuclear progestin binding was also detected. An estrogen-binding component was detected in the cytosol of 7 of 44 samples, but the binding capacity was relatively low (13 +/- 13 fmol/mg protein; mean +/- SD). During isoelectric focusing only part of this binding component behaved as might be expected from a true estrogen receptor. Nuclear estrogen binding was not observed in two samples with detectable cytoplasmic estrogen binding. The presence of both cytoplasmic and nuclear PR suggests that in meningioma a functionally active progestin-receptor system comparable with that in other progestin target tissues is operating. In contrast to these other tissues, however, the synthesis of PR in meningioma may not be influenced by estrogens. Further research should focus on evaluating whether the growth rate of meningiomas can be modulated by antiprogestins.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6509448     DOI: 10.1097/00002826-198412000-00016

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  9 in total

1.  Expression of estrogen receptors alpha and beta in human meningiomas.

Authors:  R S Carroll; J Zhang; P M Black
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

2.  Steroid receptor status difference in recurrent intracranial meningioma and breast cancer in the same patient.

Authors:  H Magdelenat; B F Pertuiset; M Poisson; J Philippon
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

3.  Mifepristone (RU 486) treatment of meningiomas.

Authors:  S W Lamberts; H L Tanghe; C J Avezaat; R Braakman; R Wijngaarde; J W Koper; H de Jong
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-06       Impact factor: 10.154

4.  Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression.

Authors:  Katariina Korhonen; Tiina Salminen; Jani Raitanen; Anssi Auvinen; Jorma Isola; Hannu Haapasalo
Journal:  J Neurooncol       Date:  2006-05-13       Impact factor: 4.130

5.  Progesterone receptor, bc1-2 and bax expression in meningiomas.

Authors:  F M Verheijen; G H Donker; C Sales Viera; M Sprong; H M Jacobs; G Blaauw; J H H Thijssen; M A Blankenstein
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

6.  Angiogenesis and expression of estrogen and progesterone receptors as predictive factors for recurrence of meningioma.

Authors:  Patricia Guevara; Elizabeth Escobar-Arriaga; David Saavedra-Perez; Abelardo Martinez-Rumayor; Diana Flores-Estrada; Daniel Rembao; Alejandra Calderon; Julio Sotelo; Oscar Arrieta
Journal:  J Neurooncol       Date:  2009-12-15       Impact factor: 4.130

7.  Meningiomas in a male fetus from a hormonally dysequilibrated mother.

Authors:  R Witzke; A Hori; G Rahlf
Journal:  Childs Nerv Syst       Date:  1985       Impact factor: 1.475

8.  Progestin receptors in meningiomas. Comparison of cytosolic assays with immunocytochemical identification in cryostat and paraffin sections.

Authors:  G Blaauw; J Koudstaal; M A Blankenstein; M Debets-Te Baerts; A H Gijzen
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

9.  Sex steroid receptors in human meningiomas.

Authors:  G Blaauw; M A Blankenstein; S W Lamberts
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.